Biosimilars

Through strategic partnerships, we strive to find smarter and faster ways of getting high-quality, affordable medication to patients.

Biosimliars completed research stage

Our Pipelines For Biosimilars Beyond 2023

    Trastuzumab (MGB-003) – Reference drug: Herceptin

    Treatment of breast cancer

    Bevacizumab (MGB-004) – Reference drug: Avastin

    Treatment of ovarian cancer

    Ipilimumab (MGB-005)-Reference drug -Yervoy

    Treatment of melanoma (A type of skin cancer, that spreads metastatic and can’t be removed by surgery)